Fortress Biotech, Inc. · Small Molecule · Small Molecule
doxycycline hyclate is a small molecule developed by Fortress Biotech, Inc.. It is approved for therapeutic indications via oral (po).
| Brand Names | Targadox |
| Company | Fortress Biotech, Inc. |
| Drug Class | Small Molecule |
| Route | Oral (PO) |
| Status | Approved |
doxycycline hyclate is developed for 1 unique indication across 1 therapeutic area.
| Therapeutic Area | Condition | Phase |
|---|---|---|
| Skin and subcutaneous tissue disorders | Acne | ✓ Approved |
Prameyllawati Diaz M DM, van Hoorn Evelien S ES
Zaheer Summera S, Coffie Sharron S
Controlled substance diversion amid the opioid epidemic threatens patients, health care workers, organizations, and communities, underscoring the need for effective prevention and response strategies within health systems. A 3-year performance improvement initiative at a large academic medical center was undertaken to enhance awareness of medication safety related to controlled substance (CS) chain of custody. This article describes the implementation of CS medication safety rounds (CSMSRs) across three phases, with a primary focus on Phase III (2023-2024). Using a Plan-Do-Study-Act (PDSA) framework, a seven-member interdisciplinary team implemented CSMSRs in ambulatory clinics, pharmacies, inpatient nursing units, and procedural areas. Proactive on-site evaluations engaged nurses and provided real-time feedback, improving adherence to best practices and strengthening CS safety and accountability. Nurses reported appreciation for the in-person CSMSRs and the opportunity to engage in dialogue regarding their adherence to institutional policies, equipment management, education options, and meaningful staff support resources. CSMSRs provided a platform for open dialogue, anonymous feedback, psychological safety, and accountability in CS management. Continued rounds are expected to engage nurses in sustaining safe practices, advancing opioid stewardship, and strengthening a culture of patient and employee safety.
Margherita Zamboni is a Postdoctoral Research Fellow in Enric Llorens's lab at the Karolinska Institute in Sweden, where she studies gene regulation in the central nervous system (CNS) in injury and regeneration. A unifying theme across her doctoral and postdoctoral work has been deciphering the molecular mechanisms that govern injury response and repair mechanisms in the mammalian CNS. She is now one of Development's Pathway to Independence programme fellows. We caught up with her to learn about her journey into science and her career path, what she hopes to get out of the programme and the questions she wants to ask in her own group.
Rairat Tirawat T, Keetanon Arunothai A, Kitsanayanyong Lalitphan L, Uchuwittayakul Anurak A et al.
Vibrio spp. are the most common opportunistic pathogens in shrimp farms, and drug-resistant Vibrio spp. pose a major threat to both shrimp and human health. The current study investigated species diversity and antimicrobial susceptibility of Vibrio spp. from Pacific white shrimp (Litopenaeus vannamei) in Southern Thailand. Shrimp were collected from ten intensive farms with a history of disease outbreaks. Vibrio spp. were isolated from the hepatopancreas, identified to species level via 16S rRNA sequencing, and tested for minimum inhibitory concentrations (MICs) against eight antibiotics. A total of 27 Vibrio species were recovered. V. parahaemolyticus was the most frequently recovered species among the selected isolates, followed by V. alginolyticus and V. harveyi. Overall, the isolates were susceptible to oxytetracycline, doxycycline, ciprofloxacin, enrofloxacin, and florfenicol, with MIC50 ranging from ≤ 0.25 to 2 μg/mL. Conversely, most Vibrio spp. were resistant to amoxicillin, ceftriaxone, and sulfadimethoxine, with MIC50 values of at least 128 μg/mL. To our knowledge, this study provides the first evidence of high-level ceftriaxone resistance in Vibrio spp. from farmed shrimp. To distinguish fully susceptible bacteria (wild type) from those that develop acquired resistance, epidemiological cut-off (COWT) was determined. The COWT for florfenicol was calculated as ≤ 4 μg/mL; when this threshold was applied to the Vibrio spp. isolates, 83.10% were classified as wild type. Our findings highlight the need for strict regulation of antibiotic use in shrimp aquaculture to minimize the emergence and spread of antibiotic-resistant bacteria.
Liu Hao H, Meijer Sebastiaan S, Wang Donghai D, Liu Lu L et al.
Background: At present, the business processes of hospital medical waste classification management are mainly completed by manual work. The related business procedures are complex, time-consuming, and laborious, the digitization level of classification business is low, and data collection is difficult. These problems have seriously affected the daily management of hospital medical waste.Objective: Radio Frequency Identification (RFID) technology provides new ideas for solving these problems. The research purpose of this article is to use RFID technology to change the business operation mode and data collection management method of medical waste classification, and improve the digitization level of medical waste classification management.Methods: The business process of hospital medical waste classification management is divided into two stages: departmental generation, cleaning and classification. Based on the two-stage business scenario and RFID technology, this paper adopts a multi-agent modeling approach to design a multi-agent simulation model for hospital medical waste classification management integrated with an RFID system.Results: An RFID dataset containing 10 key data fields of hospital medical waste classification management was refined and formed. The two-stage business scenario and RFID simulation data stream are presented. It enables the automatic collection and real-time tracking of data in each business process of medical waste classification management.Conclusions: This study provides a technical model of the RFID-medical waste classification management system, and explains the setting and usage of key data fields in each business link, which provides technical application scenarios and theoretical methods support for decision-making of medical waste classification management.
Bentham James R JR, Neervoort Jet J, Louwsma Timon T, Wolters Lambertus F LF et al.
This study evaluated the cost-effectiveness and budget impact of two patent foramen ovale (PFO) closure devices and medical management for the prevention of recurrent PFO-associated strokes in the UK. We used a Markov model to simulate 1000 individuals with a history of PFO-associated stroke over a five-year time horizon. Treatment options included GORE® CARDIOFORM Septal Occluder (GSO Device), Amplatzer™ Talisman PFO Occluder (ATO Device), and Medical Therapy Alone. Effectiveness data were drawn from the REDUCE and RESPECT trials and prior cost-effectiveness analyses (CEAs). No head-to-head clinical trial comparing the ATO and GSO Device was identified; therefore, comparative clinical effectiveness estimates were derived from a matching-adjusted indirect comparison (MAIC). Costs were assessed from a UK payer perspective (2023 GBP). Outcomes included quality-adjusted life-years (QALYs), prevented strokes, incremental cost-effectiveness ratio (ICER), and budget impact. GSO Device was estimated to be cost-saving and generate 24.66 additional QALYs versus ATO Device (dominant ICER) over five years and in a cohort of 1000 patients. Compared with Medical Therapy Alone, it provided 406.66 additional QALYs at an ICER of £14,343/QALY. It also prevented 27.86 and 67.05 strokes versus ATO Device and Medical Therapy Alone, respectively. The use of GSO Device is a cost-effective option for the prevention of secondary PFO-associated strokes, with favorable estimated clinical outcomes. Future studies providing direct comparative evidence between GSO and ATO could further inform the relative clinical and cost-effectiveness of available PFO closure devices.
+9996 more articles available with a free account
Sign up free to view all articles →